This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
1
0
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- Jefferies analyst David Stanton downgraded the rating for Mesoblast Limited (NASDAQ:MESO) from Buy to Hold. Mesoblast shares closed at $14.63 on Friday.
Full story available on Benzinga.com
Visited 1 times, 1 visit(s) today
Related posts:
- Home Run To Homewrecker – Analyst Cautious On Homebuilders, Downgrades Key Players
- Aclaris Therapeutics’ ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
- Archer-Daniels-Midland’s Financial Figures ‘Are Too High,’ Analyst Downgrades Stock
- After 130% Surge, AMD Faces Uncertain Road Ahead: Top Analyst Says Chipmaker’s Future Shrouded In Doubt